AI Generated Image
FDA scientists flag concerns with peptides as RFK Jr. tries to ease access : NPR
NPR • • business
Key Points:
- Health Secretary Robert F. Kennedy Jr. advocates for loosening restrictions on certain peptide therapies, while FDA scientists recommend maintaining current limitations due to insufficient evidence.
- The FDA recently highlighted safety concerns and a lack of consistent clinical data for peptides like BPC-157, TB-500, and MOTs-C, which are popular for wellness and longevity but lack rigorous human trials.
- These peptides, often used via subcutaneous injections for injury recovery and metabolism, were restricted by the Biden administration in 2023, limiting their availability through compounding pharmacies.
- An FDA panel with industry ties is set to review the evidence on seven peptides in July, assessing their use for conditions such as ulcerative colitis, wound healing, obesity, and migraines, but the panel's recommendations remain uncertain.
- Despite enthusiasm from some officials and users, the scientific consensus underscores a lack of robust evidence to support broader approval or use of these peptide therapies.
